Pain Therapeutics, Inc. (NASDAQ:PTIE)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $1.48. Pain Therapeutics shares last traded at $1.40, with a volume of 1,386,754 shares traded.
The firm has a 50-day moving average of $1.33.
An institutional investor recently raised its position in Pain Therapeutics stock. BlackRock Inc. grew its stake in Pain Therapeutics, Inc. (NASDAQ:PTIE) by 11.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 226,066 shares of the biopharmaceutical company’s stock after buying an additional 23,204 shares during the quarter. BlackRock Inc. owned 1.31% of Pain Therapeutics worth $193,000 at the end of the most recent reporting period. 17.40% of the stock is owned by institutional investors.
Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.
Featured Article: Market Perform
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.